Press release
New Drug Combination Could Control Blood Sugar And Weight In Diabetes
Scientists have shown that adding an experimental cancer drug to a widely used diabetes treatment improves blood sugar control and weight loss in mice, according to a study published on 22nd, Dec. in eLife.The results pave the way for clinical studies of the new drug combination as a more effective long-term treatment for millions of people with diabetes and obesity.
Glucagon-like peptide 1 agonists (GLP-1 analogs) are a relatively new class of drugs that reduce blood sugar levels and lower body weight. They partially function by binding to the glucagon-like peptide 1 receptor on pancreatic beta cells, which leads the cells to produce insulin. But not all patients achieve normalisation of blood glucose control with GLP-1 drugs, and very few achieve full reversal of obesity.
"We have previously shown that prolonged association of the GLP-1 agonists with the glucagon-like peptide 1 receptor supports insulin secretion in pancreatic beta cells," explains project team leader Dr. Prasenjit Mitra of the Dr. Reddy's Institute of Life Sciences. "This led us to see whether we could enhance the effects of GLP-1 agonism on regulating glucose levels with a complementary therapy."
The team started with a library of potential drugs and tested them in pancreatic beta cells to see if they enhanced the effects of a GLP-1 drug on incretin receptor activity, by measuring a second messenger molecule called cAMP. They found four molecules that enhanced GLP-1 drug activity. The most effective one, MS-275 (also called entinostat), generated 3.5 times the cAMP levels than the GLP-1 drug alone. MS-275 is a member of a drug family called class 1 HDAC inhibitors that are being investigated as treatments for other diseases including cancer.
Given the synergistic effect of the drugs in pancreatic beta cells, the team tested whether their findings would hold true in obese mice, fed a high-fat diet. Shilpak Bele, the graduate student under Dr. Mitra's direction, and other team members found that mice treated with the combination of GLP-1 agonist and MS-275 had a much lower fasting glucose level than control mice that were sustained with repeat dosing. Where a high-fat diet increased fasting blood sugar in the untreated mice, the mice on the combination treatment remained in control.
Given these effects on blood sugar, the team explored whether the combination treatment also minimised weight gain. Mice given the combination treatment had a significant and sustained reduction in their food intake, which resulted in weight loss. When treatment was interrupted, the mice regained weight. Once the treatment was resumed, only the mice receiving the combination treatment showed significant weight loss again.
"GLP-1 drugs have emerged in the last decade as unique medicines that provide substantial improvements in glycemic control and body weight; however, they seldom achieve full metabolic recovery or help treat associated comorbidities such as body weight," Dr. Mitra explains. "Our results suggest that the class 1 HDAC inhibitor MS-275 can significantly enhance the action of GLP-1 drugs, more effectively normalising blood glucose and reducing weight gain. This lays the foundation for clinical studies of combinations of GLP-1/HDAC inhibitors for the long-term management of diabetes and obesity in humans."
Semaglutide is a medication used for the treatment of type 2 diabetes. It acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. Liraglutide is a GLP-1 receptor agonist used to treat diabetes mellitus type 2 and obesity.
Hunan Huateng Pharmaceutical Co. Ltd.
Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Website: https://en.huatengsci.com/
Email:sales@huatengusa.com
Huateng Pharma is a leading supplier for a variety of pharmaceutical intermediates used in research and development. We can provide antidiabetic drugs intermediates such as liraglutide intermediates and semaglutide intermediates for your research. We can make scale-up production with capacities varying from gram to kilograms and multi tons.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Drug Combination Could Control Blood Sugar And Weight In Diabetes here
News-ID: 2217347 • Views: …
More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (C …
Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s. In later clinical applications, doctors observed hair regrowth and generalized excessive hair in balding patients, which led to the development of minoxidil preparations.
Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote…

Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock
Diabetes is a serious chronic disease characterized by elevated blood sugar concentrations associated with the effects of abnormal beta cell biology on insulin action. Diabetes occurs when the pancreas does not produce enough insulin or the body does not use the insulin it does produce efficiently.
The most common forms of diabetes are type 1 diabetes and type 2 diabetes. Type 1 diabetes is characterized by insufficient insulin production and…

Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of …
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer - that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.
The majority…

ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
More Releases for Mitra
Author's Tranquility Press Presents: Silhouettes of Time by Maya Mitra Das
A Journey Through Time, Space, and the Depths of Imagination
Step into a world where the boundaries of reality and fantasy blur, where time bends, and where the past, present, and future intertwine in unexpected ways. In Silhouettes of Time [https://www.amazon.com/Silhouettes-Time-Maya-Mitra-Das/dp/1964810825/ref=monarch_sidesheet_image], Maya Mitra Das masterfully crafts a mesmerizing collection of short fiction, taking readers on an enthralling voyage across exotic landscapes and otherworldly dimensions.
These thought-provoking tales introduce us to infinitely curious…
Author's Tranquility Press Present Echoes of the Past by Maya Mitra Das
A Tale of Art, Passion, and the Timeless Connection Between Two Visionaries
In Echoes of the Past [https://www.amazon.com/Echoes-Past-Maya-Mitra-Das/dp/1965075894/ref=monarch_sidesheet_image], Maya Mitra Das masterfully weaves a tale of artistry, ambition, and the transcendence of creativity across centuries. This captivating novel follows the lives of two extraordinary men - separated by time but connected through their pursuit of excellence and their deep understanding of the power of creation.
A Journey Through Time - Step into…
Author's Tranquility Press Presents: Silhouettes of Time (French Edition) by May …
Unveiling Timeless Stories That Traverse the Boundaries of Time, Space, and Memory
Author's Tranquility Press is thrilled to present Silhouettes of Time (French Edition), [https://www.amazon.com/Silhouettes-Time-Maya-Mitra-Das/dp/1964810825/ref=monarch_sidesheet_image] an enchanting collection of short stories by the gifted Maya Mitra Das. With her exceptional ability to weave tales that span across time and space, Das invites readers into a world of richly imagined landscapes and captivating narratives.
Born in India and arriving in the United States…
Author's Tranquility Press Announces: Echoes of the Past by Maya Mitra Das
A Timeless Tale of Creativity, Connection, and the Endless Flow of Passion
Maya Mitra Das invites readers on a mesmerizing journey through centuries, artfully weaving together the lives of two extraordinary men whose creativity transcends time in Echoes of the Past. [https://www.amazon.com/Echoes-Past-Maya-Mitra-Das/dp/1965075894/ref=monarch_sidesheet_image] This novel explores the indelible connection between passion and purpose, illustrating how the human spirit finds expression through dedication to one's craft.
In 15th-century Florence, Niccolo Bardi is a celebrated…
Introducing Mewa Mitra: Jaipur's Premier Dry Fruits Seller
Jaipur, [08-09-2023] - Mewa Mitra, the leading dry fruits seller in Jaipur, is proud to announce its commitment to delivering the finest assortment of dry fruits, packed with flavor and essential nutrients. With a mission to provide impeccable quality and a seamless shopping experience from start to finish, Mewa Mitra has quickly become the go-to destination for dry fruit enthusiasts.
At Mewa Mitra, we understand the importance of quality and…
CBNITS Announces Appointment of Tapabrata Mitra as the New Director of Engineeri …
Fremont, CA, USA,-- CBNITS, one of the fastest-growing multinational IT companies, is pleased to announce that Mr. Tapabrata Mitra is joining the company as the new Director of Engineering. In this role, he is responsible for the operational performance of engineering and increasing the quality and efficiency of CBNITS' Engineering department.
Mr. Mitra is an accomplished leader with more than 20 years of experience in engineering, software development, cloud security, and…